7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-09-30 2015-06-30 2015-03-31 2014-09-30 2014-06-30 2014-03-31 2013-06-30 2013-03-31 2012-09-30 2012-06-30 2012-03-31 2011-09-30 2011-06-30 2011-03-31 2010-09-30 2010-06-30 2010-03-31 
      
    		                                                        
      revenues:
    		                                                        
      collaborative arrangements revenue
    		122,060,000 85,239,000 41,143,000 90,545,000 91,592,000 94,396,000 74,877,000 117,553,000 113,739,000 107,382,000 104,061,000 107,199,000 108,637,000 97,231,000 97,529,000 116,986,000 103,747,000 103,386,000 88,665,000 114,209,000 103,468,000 89,423,000 74,445,000 105,654,000 130,524,000 77,322,000 66,152,000 84,352,000 54,194,000 71,207,000 63,086,000 62,901,000 86,143,000 64,612,000 51,877,000 87,459,000 66,106,000 54,350,000 66,042,000 39,572,000 27,744,000 28,932,000 16,918,000 6,840,000 14,605,000 9,663,000 3,255,000 96,413,000 14,604,000 12,248,000 12,218,000 11,262,000 10,237,000 9,059,000   
      total revenues
    		122,060,000 85,239,000 41,143,000 90,545,000 91,592,000 94,396,000 74,877,000 117,553,000 113,739,000 107,382,000 104,061,000 107,199,000 108,637,000 97,231,000 97,529,000 117,130,000 103,747,000 104,031,000 88,845,000 116,680,000 103,468,000 89,432,000 79,943,000 126,301,000 131,167,000 102,215,000 68,730,000 130,692,000 65,686,000 81,106,000 69,155,000 94,208,000 86,825,000 65,077,000 52,166,000                      
      costs and expenses:
    		                                                        
      research and development
    		22,468,000 23,373,000 27,432,000 25,391,000 29,827,000 30,388,000 25,815,000 35,676,000 32,985,000 34,577,000 12,847,000 10,446,000 11,545,000 11,452,000 10,822,000 31,851,000 10,907,000 12,163,000 15,484,000 16,267,000 21,692,000 22,076,000 28,027,000 26,537,000 27,551,000 28,758,000 53,990,000 44,272,000 46,794,000 38,932,000 36,505,000 40,117,000 37,065,000 37,344,000 33,702,000 38,442,000 37,526,000 31,682,000 31,842,000 25,830,000 28,648,000 26,641,000 25,122,000 22,142,000 27,144,000 24,093,000 32,753,000 23,453,000 32,238,000 29,510,000 22,905,000 19,409,000 19,555,000 18,742,000 20,953,000 18,637,000 
      selling, general and administrative
    		21,908,000 16,795,000 24,260,000 33,590,000 36,113,000 36,964,000 37,605,000 38,667,000 36,046,000 52,484,000 31,117,000 28,390,000 28,619,000 30,124,000 28,861,000 28,687,000 27,742,000 27,052,000 27,652,000 33,982,000 34,928,000 34,643,000 36,450,000 39,190,000 40,919,000 43,246,000 64,741,000 58,179,000 55,248,000 68,363,000 61,923,000 57,953,000 61,774,000 57,792,000 55,604,000 55,208,000 44,987,000 36,918,000 36,168,000 30,439,000 32,955,000 30,346,000 28,535,000 29,299,000 29,924,000 30,870,000 33,374,000          
      restructuring
    		2,200,000 -250,000 18,559,000 73,000 16,000 2,067,000                                                   
      total costs and expenses
    		46,576,000 39,918,000 70,251,000 59,054,000 65,956,000 69,419,000 63,857,000 79,964,000 73,716,000 1,190,521,000                                               
      income from operations
    		75,484,000 45,321,000 -29,108,000 31,491,000 25,636,000 24,977,000 11,020,000 37,589,000 40,023,000 -1,083,139,000 60,097,000 68,363,000 68,473,000 55,655,000 57,846,000 56,592,000 65,171,000 65,098,000 45,398,000 51,384,000 45,616,000 32,713,000 13,227,000 49,593,000 65,887,000 21,577,000 -54,372,000 5,995,000 -169,099,000 -39,920,000 -35,868,000 22,765,000 -19,434,000 -41,011,000 -39,705,000 -6,300,000 -28,287,000           47,608,000         
      yoy
    		194.45% 81.45% -364.14% -16.22% -35.95% -102.31% -81.66% -45.02% -41.55% -2046.17% 3.89% 20.80% 5.07% -14.51% 27.42% 10.14% 42.87% 99.00% 243.22% 3.61% -30.77% 51.61% -124.33% 727.24% -138.96% -154.05% 51.59% -73.67% 770.12% -2.66% -9.66% -461.35% -31.30%                        
      qoq
    		66.55% -255.70% -192.43% 22.84% 2.64% 126.65% -70.68% -6.08% -103.70% -1902.32% -12.09% -0.16% 23.03% -3.79% 2.22% -13.16% 0.11% 43.39% -11.65% 12.64% 39.44% 147.32% -73.33% -24.73% 205.36% -139.68% -1006.96% -103.55% 323.59% 11.30% -257.56% -217.14% -52.61% 3.29% 530.24% -77.73%                     
      operating margin %
    		                                                        
      other income:
    		                                                        
      interest expense and other financing costs
    		-8,434,000 -8,356,000 -8,070,000 -8,914,000 -9,419,000 -7,470,000 -7,231,000 -8,423,000 -9,839,000 -1,840,000                                               
      interest and investment income
    		930,000 818,000 869,000 778,000 1,152,000 1,369,000 1,169,000 1,194,000 1,748,000 8,757,000 7,272,000 5,446,000 2,807,000 1,018,000 230,000 180,000 178,000 172,000 196,000 220,000 231,000 276,000 777,000 565,000 893,000 668,000 736,000 837,000 741,000 732,000 681,000 619,000 601,000 496,000 395,000 346,000 307,000 295,000 221,000 156,000 71,000 65,000 71,000 65,000 44,000 49,000 52,000 41,000 44,000 49,000 105,000 125,000 154,000 188,000 189,000 68,000 
      other
    		40,000 39,000 37,000                                                      
      other income
    		-7,464,000 -7,499,000 -7,164,000 -7,496,000 -8,267,000 -6,101,000 -6,062,000 -7,229,000 -8,091,000 6,917,000 5,764,000 -454,250 1,434,000 -1,870,000 -1,381,000     -3,000   27,000 306,000 68,000 140,000 -4,912,000 -21,488,000 -5,252,000 -9,460,000 -7,276,000 -7,218,000 -12,863,000 -3,213,000 -12,796,000 -5,658,250 -4,917,000              897,000  3,000 107,000 110,000  
      income before income taxes
    		68,020,000 37,822,000 -36,272,000 23,995,000 17,369,000 18,876,000 4,958,000 30,360,000 31,932,000 -1,076,222,000 65,861,000 72,265,000 69,907,000 53,785,000 56,465,000 38,600,500 59,672,000 54,372,000 40,358,000                                      
      income tax expense
    		-27,940,000 -14,223,000 -1,114,000 -21,739,000 -13,723,000 -19,736,000 -9,120,000 -12,846,250 -17,982,000 -13,256,000 -20,147,000    -17,664,000    -432,000 1,296,000 1,389,000                                    
      net income
    		40,080,000 23,599,000 -37,386,000 2,256,000 3,646,000 -860,000 -4,162,000 -1,745,000 13,950,000               47,858,000 20,648,000 12,283,000 -59,284,000 -15,493,000 -174,351,000 -49,380,000 -43,144,000 12,085,000 -32,297,000 -44,224,000 -52,501,000 -13,505,000 -33,204,000 -21,702,000 -13,297,000 -47,390,000 -48,020,000 -33,222,000 -41,988,000 -60,357,000 -49,626,000 -65,149,000 -93,902,000 47,635,000 -40,803,000        
      yoy
    		999.29% -2844.07% 798.27% -229.28% -73.86%                   -408.90% -111.84% -124.87% 37.41% -228.20% 439.84% 11.66% -17.82% -189.49% -2.73% 103.78% 294.83% -71.50% -30.85% -34.68% -68.33% -21.48% -3.24% -49.01% -55.29% -226.71% 21.62%            
      qoq
    		69.84% -163.12% -1757.18% -38.12% -523.95% -79.34% 138.51% -112.51%                131.78% 68.10% -120.72% 282.65% -91.11% 253.08% 14.45% -457.00% -137.42% -26.97% -15.77% 288.75% -59.33% 53.00% 63.21% -71.94% -1.31% 44.54% -20.88% -30.43% 21.62% -23.83% -30.62% -297.13% -216.74%         
      net income margin %
    		                                                        
      ​
    		                                                        
      net income per share
    		0.25 0.15 -0.23 0.02 0.02 -0.01 -0.03  0.1 -6.84 0.3 0.31 0.33 0.24 0.25 0.25 0.34 2.42 0.25 0.27 0.22 0.16 0.02 0.31 0.13 0.08 -0.38 -0.1 -1.14 -0.32 -0.29 0.09 -0.22 -0.3 -0.36 -0.09 -0.23 -0.15 -0.09 -0.33 -0.34 -0.24 -0.3 -0.44 -0.38 -0.57 -0.87  -0.38 -0.34 -0.21 -0.19 -0.19 -0.08 -0.18 -0.25 
      weighted-average shares used for eps calculation
    		162,215 161,723 160,974 159,083 159,706 159,014 157,700 155,435 155,886 155,367 154,452 154,366 153,066 153,304 157,821 162,245 162,742 161,948 160,967 159,427 159,846 159,407 158,374                                  
      acquired in-process research and development
    		       5,000,000  1,090,449,000                                               
      gain on derivatives
    		          19,000 -18,000 151,000 -681,000 730,000 -2,566,000 2,164,000  2,390,000   -467,000 -3,466,000 4,517,000 -4,766,000 -672,000 3,944,000 -12,739,000 3,489,000 -809,000 1,316,000 -2,093,000 -4,329,000 5,337,000  2,103,000 4,541,000 3,145,000                   
      less: net income attributable to noncontrolling interests
    		       -658,000 -1,371,000                                                
      net income attributable to ironwood pharmaceuticals, inc.
    		   2,256,000 3,646,000 -860,000  -1,087,000 15,321,000                                          -20,633,000 -18,844,000 -18,401,000 -8,270,000 -17,136,000 -15,924,000 
      restructuring expenses
    		      437,000 621,000 4,685,000 13,011,000       -73,000 -282,000 311,000 14,150,000 1,232,000   -32,000 -166,000 490,000 3,328,000 783,000 10,282,000 2,392,000                           
      net income and comprehensive income
    		         -1,089,478,000 45,714,000 48,867,000 50,317,000 37,080,000 38,801,000 41,374,000 55,845,000 391,303,000 39,926,000 15,743,000 34,423,000 25,204,000 3,345,000                                  
      less: net income and comprehensive income attributable to noncontrolling interests
    		         -27,291,000                                               
      net income and comprehensive income attributable to ironwood pharmaceuticals, inc.
    		         -1,062,187,000                                               
      operating expenses:
    		                                                        
      total operating expenses
    		          43,964,000 38,836,000 40,164,000 41,576,000 39,683,000                                 48,805,000 55,438,000 47,884,000 33,834,000 30,214,000 28,779,000 25,224,000 28,278,000 25,280,000 
      interest expense
    		          -1,527,000 -1,526,000 -1,524,000 -2,207,000 -2,341,000 -7,951,000 -7,841,000 -7,732,000 -7,626,000 -7,521,000 -7,419,000 -7,318,000 -7,220,000 -7,123,000 -10,457,000 -9,430,000 -9,592,000 -9,586,000 -9,482,000 -9,383,000 -9,273,000 -9,206,000 -9,135,000 -9,046,000 -8,983,000 -9,654,000 -9,765,000                    
      sale of active pharmaceutical ingredient
    		               144,000  645,000 180,000 2,471,000  9,000 5,498,000 20,647,000 643,000 24,893,000 2,578,000 45,861,000 10,257,000 8,803,000 5,434,000                          
      income tax benefit
    		           -23,398,000 -19,590,000 -16,705,000  -4,881,000 -3,827,000 336,931,000                                 3,000      
      cost and expenses:
    		                                                        
      cost of revenues
    		                   559,750   2,239,000                                  
      total cost and expenses
    		               60,538,000 38,576,000 38,933,000 43,447,000 65,296,000 57,852,000 56,719,000 66,716,000 76,708,000 65,280,000 80,638,000 123,102,000 124,697,000 234,785,000 121,026,000 105,023,000 71,443,000 106,259,000 106,088,000 91,871,000 93,759,000 94,393,000 69,665,000 68,010,000 65,757,000 69,753,000 56,999,000 53,657,000 61,959,000 58,992,000 69,543,000 92,088,000          
      loss on derivatives
    		                 -3,166,000  -1,637,250 -2,616,000              -2,199,000                      
      write-down of commercial supply and inventory to net realizable value and settlement on non-cancellable purchase commitments
    		                                                        
      gain on lease modification
    		                         -3,169,000                               
      loss on extinguishment of debt
    		                        -30,977,000          -2,009,000                      
      income from continuing operations, before income taxes
    		                   44,500,000 35,812,000                                    
      income from continuing operations, net of income taxes
    		                   15,743,000 34,423,000                                    
      income from discontinued operations, net of income taxes
    		                                                        
      income per share from continuing operations, net of income taxes—basic
    		                   0.27 0.22                                    
      income per share from continuing operations, net of income taxes—diluted
    		                   0.27 0.21                                    
      loss per share from discontinued operations, net of income taxes—basic and diluted
    		                                                        
      net income from continuing operations
    		                     25,204,000 3,345,000 47,858,000 20,648,000 12,283,000                               
      net income from discontinued operations
    		                                                     9,311,000   
      product revenue
    		                           479,000 1,235,000 1,096,000 635,000 1,625,000 682,000 465,000 289,000                      
      cost of revenues, excluding amortization of acquired intangible assets
    		                       11,013,000 506,000 11,313,000 1,043,000 21,463,000 4,616,000 4,065,000 2,607,000 2,528,250 6,080,000                        
      write-down of commercial supply and inventory to net realizable value and (settlement) loss on non-cancellable purchase commitments
    		                        -3,530,000   61,750 -1,589,000                            
      amortization of acquired intangible assets
    		                            1,159,000 3,476,000 3,476,000 684,500 1,897,000                        
      gain on fair value remeasurement of contingent consideration
    		                                                        
      impairment of intangible assets
    		                            151,794,000                            
      weighted-average number of common shares—basic and diluted:
    		                        156,436 155,849                               
      write-down of commercial supply and inventory to net realizable value and loss on non-cancellable purchase commitments
    		                             1,836,000                           
      loss on fair value remeasurement of contingent consideration
    		                             1,962,000 512,000   6,933,000 1,614,000 1,164,000 8,667,000                    
      weighted-average number of common shares used in net income per share—basic and diluted:
    		                          154,956 152,634 153,227 152,163 151,013 148,993 149,502 148,778 147,786 144,928 145,180                    
      (gain) loss on fair value remeasurement of contingent consideration
    		                            -33,519,000   -39,229,000 -628,000                        
      write-down of lesinurad commercial supply to net realizable value
    		                               41,750 71,000                        
      cost of revenues, excluding amortization of acquired intangible asset
    		                                 3,502,000 531,000                      
      write-down of lesinurad commercial supply to net realizable value and loss on non-cancellable purchase commitments
    		                                 96,000                       
      amortization of acquired intangible asset
    		                                 421,000 420,000 -3,297,000 3,213,000 1,065,000                   
      cost of revenue, excluding amortization of acquired intangible asset
    		                                                        
      write-down of inventory to net realizable value and loss on non-cancellable purchase commitments
    		                                       9,488,000                 
      weighted-average number of common shares used in net income per share — basic and diluted:
    		                                     144,642 143,593 142,473 142,098 141,278 139,234 138,315 129,745 113,441,391 108,072,643          
      cost of revenue
    		                                        8,150,000 12,000  10,518,000 1,924,000 3,418,000 1,231,000          
      gross profit
    		                                                        
      yoy
    		                                                        
      qoq
    		                                                        
      gross margin %
    		                                                      0% 0% 
      collaboration expense
    		                                             11,162,000 24,730,000          
      general and administrative
    		                                               25,352,000 23,200,000 18,374,000 10,929,000 10,805,000 9,224,000 6,482,000 7,325,000 6,643,000 
      net income before income taxes
    		                                               47,635,000         
      basic net income per share
    		                                               0.44         
      diluted net income per share
    		                                               0.42         
      weighted-average number of common shares used in:
    		                                                        
      comprehensive income
    		                                               47,651         
      weighted-average number of common shares used in net income per share —basic and diluted
    		                                                107,078,150 103,751,060       
      comprehensive loss
    		                                                -40,815 -35,604,000       
      other comprehensive income:
    		                                                        
      unrealized gain on short-term investments
    		                                                        
      other comprehensive income
    		                                                        
      net income from continuing operations before income tax benefit
    		                                                        
      net income from discontinued operations attributable to noncontrolling interest
    		                                                        
      continuing operations
    		                                                  -0.21 -0.19 -0.19 -0.16   
      discontinued operations
    		                                                     0.08   
      weighted-average number of common shares used in net income per share attributable to ironwood pharmaceuticals, inc.—basic and diluted
    		                                                  100,174,100 99,674,969 99,075,187 97,925,657 97,642,330 63,957,966 
      remeasurement of forward purchase contracts
    		                                                        
      net (income) income from discontinued operations attributable to noncontrolling interest
    		                                                        
      revenue:
    		                                                        
      collaborative arrangements
    		                                                      9,188,000 8,838,000 
      services
    		                                                      1,771,000 214,000 
      total revenue
    		                                                      10,959,000 9,052,000 
      yoy
    		                                                        
      qoq
    		                                                      21.07%  
      net income attributable to noncontrolling interest
    		                                                      73,000 329,000 
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.